Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

477
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
477
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.7K
Clinical Trials01:16

Clinical Trials

9.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.5K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to recent technical tip describing screw length measurement technique.

Annals of the Royal College of Surgeons of England·2026
Same author

Next-generation multicenter studies: using artificial intelligence to automatically process unstructured health records of patients with lung cancer across multiple institutions.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

The unjustified fear of erdafitinib-induced central serous retinopathy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Representation of geriatric oncology in cancer care guidelines in Europe: a scoping review by the International Society of Geriatric Oncology (SIOG).

ESMO open·2025
Same author

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial.

ESMO open·2025
Same author

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.

ESMO open·2024

Related Experiment Video

Updated: Oct 6, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

555

11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentation.

H K van Halteren1, A Tan2, B Pellegrino3

  • 1Department of Medical Oncology, Adrz Hospital, Goes, The Netherlands.

ESMO Open
|January 20, 2022
PubMed
Summary
This summary is machine-generated.

The European Society for Medical Oncology 2021 conference highlighted practice-changing cancer trial results. However, presentations often lacked methodological details and clear links to clinical benefit, necessitating full journal publications for thorough evaluation.

Keywords:
clinical benefitcurative treatmentmethodologypalliative treatmentphase IIIsolid cancers

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.2K

Related Experiment Videos

Last Updated: Oct 6, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

555
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.2K

Area of Science:

  • Oncology
  • Clinical Trials
  • Evidence-Based Medicine

Background:

  • The European Society for Medical Oncology (ESMO) 2021 conference featured numerous randomized phase III trials.
  • Many trials were presented as practice-changing, but with limited time for detailed methodology.
  • Presentations prioritized results and conclusions over study background and methods.

Purpose of the Study:

  • To evaluate 11 selected potentially practice-changing reports from the ESMO 2021 conference.
  • Assessed the comprehensibility of results based on provided patient and methods details.
  • Investigated potential bias and the translation of results into clinical benefit.

Main Methods:

  • Screening of 11 selected ESMO 2021 conference reports.
  • Comparison of presented study designs with those registered on ClinicalTrials.gov.
  • Analysis of allocation concealment, handling of censoring and crossover, and defined outcome measures.

Main Results:

  • Discrepancies between presented and registered study designs were found in 2 out of 11 trials.
  • Allocation concealment was inadequate in 6 out of 11 trials.
  • Outcome measures and claims of study success were often unclearly linked to clinical benefit, with missing details on informative censoring and desirable crossover.

Conclusions:

  • ESMO conference presentations are valuable for disseminating research but do not replace full peer-reviewed publications.
  • Full papers are essential for a thorough assessment of results, clinical benefit, and impact on treatment guidelines.
  • Further scrutiny of methodology and clinical relevance is needed for practice-changing claims.